Dusquetide Reduces Duration of Oral Mucositis by Half

Share this content:
Dusquetide reduces the duration of severe oral mucositis by up to half.
Dusquetide reduces the duration of severe oral mucositis by up to half.

Dusquetide reduces the duration of severe oral mucositis (OM) by up to half, according to the results of a phase 2a study accepted for publication in the Journal of Biotechnology.1

OM is almost ubiquitous among patients with head and neck cancers, and the condition is severe in nearly 75% of patients with OM. The authors estimate that severe OM increases care-related costs by about $18,000 per patient.

In animal models, dusquetide reduced the duration of OM by about 50%; for the present study, researchers tested the efficacy of OM among human patients.

Among 96 evaluable patients of the 111 enrolled to this study, those who received dusquetide had severe OM for an average of only 9 days, as opposed to 18 days for those who received placebo. The drug did not impair tumor response to anticancer treatment.

RELATED: Chronic Sinusitis Linked With Head and Neck Cancers

Adverse events were similar in both groups.

The authors conclude that preclinical models were indicative of results in human participants. Dusquetide is efficacious for reducing OM duration and was well-tolerated by patients with head and neck cancer.


  1. Kudrimoti M, Curtis A, Azawic S, et al. Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J. Biotechnol. In press. doi: 10.1016/j.jbiotec.2016.10.010

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs